Chart-Typ:
Zeitraum:
| Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen |
| Alignment Healthcare USA, LLC: Alignment Health Unveils 2026 Medicare Advantage Plans with Strong Benefits, Expanded Support for Seniors | ORANGE, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Alignment Health Plan, an award-winning Medicare Advantage (MA) plan from Alignment Health, today announced its 2026 product portfolio, offering 68... ► Artikel lesen |
| Alignment Healthcare Reports Second Quarter 2025 Results; Raises Full-Year Outlook Across All Key Metrics | Reports total revenue of $1.0 billion in Q2 and 223,700 health plan members as of June 30, up 49.0% and 27.8% year-over-year respectively Surpasses high-end of Q2 guidance across all key metrics:... ► Artikel lesen |
| S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen |
| Natera, Inc.: Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer | Multicenter, Signatera Genome-guided interventional trial will evaluate different treatment approaches in HR+/HER2- breast cancer Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA... ► Artikel lesen |
| XFRA NEW INSTRUMENTS AVAILABLE ON 02.12.2025 | The following instruments on XETRA do have their first trading 02.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.12.2025
Aktien
1 KYG1331C1042 Blue Gold Ltd.
2 DE000A31C222... ► Artikel lesen |
| Natera: Phase 3 Trial Results Show Signatera-Guided Therapy Improves Survival In Bladder Cancer | SOUTH SAN FRANCISCO (dpa-AFX) - Natera Inc. (NTRA) announced results from the randomized, double-blind, phase 3 IMvigor011 clinical trial in muscle-invasive bladder cancer (MIBC). The findings... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIBBINSTRUMENTS AB finden Sie auf Wallstreet Online.